{"title":"Editorial: Current Approaches to Screening for Lung Cancer in Smokers and Non-Smokers.","authors":"Dinah V Parums","doi":"10.12659/MSM.948255","DOIUrl":null,"url":null,"abstract":"<p><p>In 2021, the US Preventive Services Task Force (USPSTF) called for increased efforts at tobacco control, smoking-cessation treatments, and annual lung cancer screening with low-dose computed tomography (LDCT), targeted at high-risk populations. In January 2024, the American Cancer Society (ACS) published an update on the previous 2013 lung cancer screening guidelines and recommends annual lung cancer screening with lung LDCT for individuals aged 50-80 years who are asymptomatic but who currently smoke or have previously smoked. Although rates of tobacco smoking have been falling in some countries, the incidence of lung cancer in individuals who have never smoked now represents the 7th most common cancer and the 5th leading cause of cancer-related death. Because there is evidence that lung cancer screening with LDCT reduces lung cancer mortality in individuals with a substantial smoking history, there is now increasing interest in evaluating LDCT for lung cancer screening in those who have never smoked. In 2024, the International Association for the Study of Lung Cancer (IASLC) published a five-year (2023-2027) roadmap for the global use of LDCT in screening for lung cancer. This editorial aims to highlight some recent guidelines and current approaches to lung cancer screening in smokers and non-smokers.</p>","PeriodicalId":48888,"journal":{"name":"Medical Science Monitor","volume":"31 ","pages":"e948255"},"PeriodicalIF":3.1000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11796283/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Science Monitor","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12659/MSM.948255","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
In 2021, the US Preventive Services Task Force (USPSTF) called for increased efforts at tobacco control, smoking-cessation treatments, and annual lung cancer screening with low-dose computed tomography (LDCT), targeted at high-risk populations. In January 2024, the American Cancer Society (ACS) published an update on the previous 2013 lung cancer screening guidelines and recommends annual lung cancer screening with lung LDCT for individuals aged 50-80 years who are asymptomatic but who currently smoke or have previously smoked. Although rates of tobacco smoking have been falling in some countries, the incidence of lung cancer in individuals who have never smoked now represents the 7th most common cancer and the 5th leading cause of cancer-related death. Because there is evidence that lung cancer screening with LDCT reduces lung cancer mortality in individuals with a substantial smoking history, there is now increasing interest in evaluating LDCT for lung cancer screening in those who have never smoked. In 2024, the International Association for the Study of Lung Cancer (IASLC) published a five-year (2023-2027) roadmap for the global use of LDCT in screening for lung cancer. This editorial aims to highlight some recent guidelines and current approaches to lung cancer screening in smokers and non-smokers.
期刊介绍:
Medical Science Monitor (MSM) established in 1995 is an international, peer-reviewed scientific journal which publishes original articles in Clinical Medicine and related disciplines such as Epidemiology and Population Studies, Product Investigations, Development of Laboratory Techniques :: Diagnostics and Medical Technology which enable presentation of research or review works in overlapping areas of medicine and technology such us (but not limited to): medical diagnostics, medical imaging systems, computer simulation of health and disease processes, new medical devices, etc. Reviews and Special Reports - papers may be accepted on the basis that they provide a systematic, critical and up-to-date overview of literature pertaining to research or clinical topics. Meta-analyses are considered as reviews. A special attention will be paid to a teaching value of a review paper.
Medical Science Monitor is internationally indexed in Thomson-Reuters Web of Science, Journals Citation Report (JCR), Science Citation Index Expanded (SCI), Index Medicus MEDLINE, PubMed, PMC, EMBASE/Excerpta Medica, Chemical Abstracts CAS and Index Copernicus.